Celldex Therapeutics (NASDAQ:CLDX) Trading 4.2% Higher Following Insider Buying Activity

Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 4.2% during trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $27.89 and last traded at $27.30. 107,913 shares changed hands during mid-day trading, a decline of 88% from the average session volume of 869,580 shares. The stock had previously closed at $26.21.

Specifically, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was bought at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the purchase, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CLDX shares. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Thursday, November 7th. Wolfe Research lowered shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 27th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective on the stock. Citigroup initiated coverage on Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 3.1 %

The company has a market capitalization of $1.79 billion, a PE ratio of -10.65 and a beta of 1.60. The business’s 50-day simple moving average is $33.29 and its two-hundred day simple moving average is $35.72.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Celldex Therapeutics during the second quarter worth $76,000. KBC Group NV lifted its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Headlands Technologies LLC acquired a new position in Celldex Therapeutics during the 1st quarter worth $147,000. CANADA LIFE ASSURANCE Co boosted its holdings in Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 955 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,582 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.